Parsippany, New Jersey, USA & Tel Aviv, Israel, September 16, 2026
Teva Pharmaceuticals has launched LongActingImpact.com, a new educational resource designed to help healthcare professionals better understand the role of long-acting injectable (LAI) medicines in schizophrenia care. The resource provides evidence-based information and practical guidance intended to support clinicians in treatment discussions with people living with schizophrenia. Teva said the platform focuses on the potential role of LAIs in supporting treatment adherence, reducing relapse risk and maintaining continuity of care, particularly during transitions between inpatient and outpatient settings. The initiative reflects Teva’s continued focus on neuroscience and its efforts to provide healthcare professionals with resources that can support informed treatment decision-making in schizophrenia.
Teva Expands Education on Long-Acting Injectables
LongActingImpact.com has been developed specifically for healthcare professionals and provides information covering several aspects of LAI treatment in schizophrenia. The resource discusses how long-acting formulations can help address challenges associated with taking medication every day and provides practical information for clinicians considering these treatment approaches. According to Teva, the website addresses relapse risk, consistent treatment delivery and continuity of care, including the important transition from inpatient treatment to outpatient management. The platform also offers guidance for clinicians on discussing LAIs with patients, beginning with individual treatment goals and developing ongoing conversations around treatment options. Treatment adherence is an important consideration in schizophrenia management because discontinuation or inconsistent use of antipsychotic medication can increase the risk of symptom recurrence and hospitalization. Teva cited an analysis reporting that 67% of patients taking oral medications for schizophrenia were nonadherent or discontinued treatment. The company said LAIs may offer an option for people who experience challenges with daily medication, although treatment selection should be individualized based on clinical circumstances and patient preferences.
LAIs Support Continuity in Schizophrenia Care
Long-acting injectable antipsychotics are designed to provide sustained medication delivery over extended periods, reducing the need for daily oral dosing. Depending on the specific medicine, LAIs can be administered at intervals ranging from several weeks to longer periods, according to their approved prescribing information. Teva’s educational initiative emphasizes the potential role of LAIs in helping maintain consistent treatment exposure. The company also highlights their potential relevance during transitions between healthcare settings, when continuity of medication management can be particularly important.
Advertisement
Schizophrenia is a chronic psychiatric disorder that can involve symptoms such as delusions, hallucinations, disorganized speech or behavior and impaired cognitive function. The condition affects approximately 24 million people worldwide, according to Teva’s current disease information. The long-term course can include periods of improvement and relapse, making sustained treatment and ongoing clinical monitoring important elements of disease management. The choice between oral and long-acting injectable treatment depends on multiple factors, including the patient’s clinical history, treatment response, preferences, tolerability and ability to maintain a medication schedule. The new resource is intended to help clinicians have more informed discussions rather than replace individualized medical decision-making.
Teva Strengthens Focus on Neuroscience
The launch of LongActingImpact.com builds on Teva’s established neuroscience portfolio and schizophrenia research activities. The company has been developing and commercializing long-acting injectable treatments while continuing research into additional approaches for complex neurological and psychiatric conditions. Teva’s current schizophrenia portfolio includes UZEDY® (risperidone), an extended-release injectable suspension, while the company is also advancing an investigational long-acting formulation of olanzapine. The company said the new platform was created in response to challenges identified by clinicians, including perceived patient resistance to injectable treatment and operational complexities associated with implementing LAIs in routine practice. The educational content therefore focuses not only on clinical information but also on treatment conversations and practical implementation.
For cGxP.wire readers, Teva’s initiative highlights the increasing attention being given to long-acting treatment strategies in schizophrenia, particularly as pharmaceutical companies and healthcare professionals explore ways to improve continuity of treatment. While the resource is educational rather than a new drug approval or clinical-trial announcement, it addresses an important aspect of pharmaceutical care: ensuring that appropriate treatment options are understood and considered at different stages of a patient’s care journey.
Source: Teva Pharmaceuticals press release
